Physician profile
Stacey Harmonay
NPI 1922587898
$1,625.92
in general payments reported to CMS, 2019-2025
22 companies · $423 in 2025
The $423 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2022: $272 · 2023: $524 · 2024: $293 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,148 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,147.70 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $383.76 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $241.32 | 2021-2025 | Prevymis, Zerbaxa, Dificid |
| Novartis Pharmaceuticals Corporation | $163.86 | 2023-2025 | |
| Kite Pharma, INC. | $151.21 | 2024-2025 | Yescarta |
| Astellas Pharma US INC | $105.06 | 2023-2025 | Xospata, Cresemba |
| Novocure INC. | $88.81 | 2022 | |
| Daiichi Sankyo INC. | $68.92 | 2023-2024 | Vanflyta |
| Celgene Corporation | $49.38 | 2022 | |
| Jazz Pharmaceuticals INC. | $49.32 | 2022-2024 | |
| Amgen INC. | $39.59 | 2021-2022 | |
| Emd Serono, INC. | $31.20 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $28.87 | 2021 | |
| Genmab U.S., INC. | $27.49 | 2023 | Tivdak |
| Cti Biopharma Corp. | $25.19 | 2022 | |
| Foundation Medicine, INC. | $23.82 | 2023 | Foundationone Liquid Cdx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $23.72 | 2023 | Soliris |
| Incyte Corporation | $23.20 | 2022 | |
| Rigel Pharmaceuticals, INC. | $21.87 | 2023 | Rezlidhia, Tavalisse |
| Novo Nordisk INC | $20.84 | 2022 | |
| Legend Biotech USA INC. | $20.14 | 2025 | Carvykti |
| Bayer Healthcare Pharmaceuticals INC. | $19.42 | 2022 | |
| Immunocore Limited | $18.93 | 2023 | Kimmtrak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Harmonay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.